Literature DB >> 19712581

Aberrant phosphorylation in the pathogenesis of Alzheimer's disease.

Sul-Hee Chung1.   

Abstract

The modification of proteins by reversible phosphorylation is a key mechanism in the regulation of various physiological functions. Abnormal protein kinase or phosphatase activity can cause disease by altering the phosphorylation of critical proteins in normal cellular and disease processes. Alzheimer's disease (AD), typically occurring in the elderly, is an irreversible, progressive brain disorder characterized by memory loss and cognitive decline. Accumulating evidence suggests that protein kinase and phosphatase activity are altered in the brain tissue of AD patients. Tau is a highly recognized phosphoprotein that undergoes hyperphosphorylation to form neurofibrillary tangles, a neuropathlogical hallmark with amyloid plaques in AD brains. This study is a brief overview of the altered protein phosphorylation pathways found in AD. Understanding the molecular mechanisms by which the activities of protein kinases and phosphatases are altered as well as the phosphorylation events in AD can potentially reveal novel insights into the role aberrant phosphorylation plays in the pathogenesis of AD, providing support for protein phosphorylation as a potential treatment strategy for AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712581     DOI: 10.5483/bmbrep.2009.42.8.467

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  36 in total

1.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

2.  Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling.

Authors:  Andréia M Leopoldino; Cristiane H Squarize; Cristiana B Garcia; Luciana O Almeida; Cezar R Pestana; Ana C M Polizello; Sérgio A Uyemura; Eloiza H Tajara; J Silvio Gutkind; Carlos Curti
Journal:  Mol Cell Biochem       Date:  2011-12-06       Impact factor: 3.396

Review 3.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

Review 4.  Tau in neurodegenerative disease.

Authors:  Yong-Lei Gao; Nan Wang; Fu-Rong Sun; Xi-Peng Cao; Wei Zhang; Jin-Tai Yu
Journal:  Ann Transl Med       Date:  2018-05

Review 5.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

6.  Prediction of functional phosphorylation sites by incorporating evolutionary information.

Authors:  Shen Niu; Zhen Wang; Dongya Ge; Guoqing Zhang; Yixue Li
Journal:  Protein Cell       Date:  2012-07-16       Impact factor: 14.870

Review 7.  Aβ Influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease.

Authors:  Ana Gabriela Henriques; Joana Machado Oliveira; Liliana Patrícia Carvalho; Odete A B da Cruz E Silva
Journal:  Mol Neurobiol       Date:  2014-10-26       Impact factor: 5.590

Review 8.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

9.  Calpastatin modulates APP processing in the brains of β-amyloid depositing but not wild-type mice.

Authors:  Jose Morales-Corraliza; Jason D Berger; Matthew J Mazzella; Thomas A Neubert; Jorge Ghiso; Mala V Rao; Matthias Staufenbiel; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2011-12-27       Impact factor: 4.673

10.  SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Authors:  Carlos Cruchaga; John S K Kauwe; Kevin Mayo; Noah Spiegel; Sarah Bertelsen; Petra Nowotny; Aarti R Shah; Richard Abraham; Paul Hollingworth; Denise Harold; Michael M Owen; Julie Williams; Simon Lovestone; Elaine R Peskind; Ge Li; James B Leverenz; Douglas Galasko; John C Morris; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.